Blister Package (1246 4 Blister Pack Resized)
Ondansetron Tablet, Orally Disintegrating
Product Images NDC 51662-1246
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Ondansetron (NDC 51662-1246). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Hf Acquisition Co Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
51662-1246-4 Serialized Bag (1246 4 Serialized Labeling Resized)
7b0692fd 71d7 Bd7d E053 2a91aa0a3a38
Adverse 1 (Adverse 1)
This is a table presenting the adverse reactions experienced by a group of 262 individuals who were given either Ondansetron orally or a placebo twice daily at a dose of 8mg. The table lists the incidence of four adverse reactions - headache, malaise/fatigue, constipation, and diarrhea - for both the Ondansetron group and the placebo group. The numbers indicate the number of individuals in each group who experienced each adverse reaction, and the percentages represent the percentage of individuals in each group who experienced each reaction.*
Adverse 2 (Adverse 2)
This is a table showing the incidence of side effects of ondansetron and placebo, both administered orally as disintegrating tablets, in a sample of 550 people. The dose was 16 mg as a single dose. The table shows the percentage of people who reported experiencing each side effect, including headache, hypoxia, pyrexia, dizziness, gynecological disorder, anxiety/agitation, urinary retention, and pruritus.*
Clinical 1 (Clinical Pharma 1)
Clinical Pharma 2 (Clinical Pharma 2)
This looks like a tabular format of a study report, possibly of a pharmacokinetics study. The study involves the administration of a drug (possibly fasboup) to a group of individuals between the ages of 18 and 43 with varying weights, and measuring the plasma concentration levels of the drug at different time points. The table reports the mean peak plasma concentration, time of peak, mean elimination half-life, and weight of male and female participants. However, without additional context, it is difficult to draw any conclusions about the drug's efficacy or safety.*
Clinical Studies 1 (Clinical Studies 1)
This is a comparison of the effectiveness of ondansetron orally disintegrating tablets versus placebo in treating emetic episodes. The data shows that the treatment with ondansetron resulted in significantly fewer emetic episodes compared to the placebo group. Median time to first emetic episode was also longer in the ondansetron group.*
Clinical Studies 2 (Clinical Studies 2)
The text describes the results of treatment with Ondansetron tablets at doses of 8 mg twice daily or 8 mg three times a day on a sample of 165 and 171 individuals respectively. The treatment resulted in a response of 61% and 58% with no emetic episodes, and 10% and 10% with 1-2 emetic episodes, while 29% and 32% had over 2 emetic episodes or were withdrawn. The median number of emetic episodes was zero, and the median nausea scores were 6 for both groups. Median time to the first emetic episode was undefined.*
Dosage 1 (Dosage 1)
This text provides dosing instructions for a medication given before highly emetogenic chemotherapy or radiotherapy to prevent nausea and vomiting. The recommended dosage varies depending on the type of radiotherapy and ranges from a single 24 mg dose to multiple 8 mg doses given over several days.*
Dosage 2 (Dosage 2)
This text provides dosage regimens for administering medication to children between the ages of 4 and 17 undergoing chemotherapy for emetogenic cancer. The recommended dosages are given for 8mg and 4mg and vary in frequency from every 12 hours to every 8 hours. The medication should be administered before and after chemotherapy for a period of 1 to 2 days.*
Structure (Structure)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
